Using clozapine to reduce violence in people with schizophrenia
5/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
This study is looking at whether clozapine, a medication for schizophrenia, can help reduce the chances of violent behavior in people who are at high risk, and it’s for individuals with schizophrenia who might benefit from a new treatment option.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nathan S. Kline Institute for Psych Res NIH-funded |
| Lab location | 1 site (Orangeburg, United States) |
| Project ID | NIH-10876287 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of clozapine, an antipsychotic medication, in reducing the risk of violent behavior among individuals diagnosed with schizophrenia who are at high risk for violence. The study will involve a randomized clinical trial across seven sites, where participants will receive either clozapine or standard treatment for a duration of 24 weeks. By focusing on real-world community settings, the research aims to provide more generalizable results compared to previous studies. The primary goal is to measure the time until any violent acts occur among participants, contributing valuable data to improve treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who exhibit a high risk of violent behavior.
Not a fit: Patients with schizophrenia who are not at risk for violence or those who do not meet the study's inclusion criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for reducing violence in individuals with schizophrenia, ultimately improving their quality of life and reducing stigma.
How similar studies have performed: Previous studies have suggested that clozapine may be more effective than other antipsychotics in reducing aggression, but this trial aims to provide robust evidence through a well-designed randomized clinical trial.
Where this research is happening
Orangeburg, United States
- Nathan S. Kline Institute for Psych Res — Orangeburg, United States (Active)
Researchers
- Principal investigator: Lindenmayer, Jean-Pierre — Nathan S. Kline Institute for Psych Res
- Study coordinator: Lindenmayer, Jean-Pierre
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.